Post-Brexit medicines - stuck in the UK?
Following the EMA’s most recent survey, which concerned pharmaceutical companies’ preparedness for Brexit, it became apparent that very little guidance had been given to businesses on how best to prepare for the change.
As a CDMO with a presence in both the UK and mainland Europe, we are well positioned to support our customers through the Brexit transition.
In fact, the EMA has revealed that the supply of more than 100 medicines manufactured solely in the UK is at risk of disruption post-Brexit. This is because the necessary work to ensure they can be licensed and released for sale in mainland Europe has not been carried out.
CPhI Online spoke to Thomas Beck, senior vice president, quality management at Recipharm, to discuss the implications of Brexit in light of this new information.
For the full article see here.